Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Thomas Jefferson University
Case Comprehensive Cancer Center
Stanford University
OHSU Knight Cancer Institute
St. Jude Children's Research Hospital